Objective: Almost every country in the developed world has a domiciliary oxygen program. Whether recipients meet program criteria has not been rigorously studied. Design: Cross-sectional survey. Participants: Two hundred thirty-seven patients receiving domiciliary oxygen in the Ontario Ministry of Health Home Oxygen Program (HOP). Methods: A respiratory therapist visited the patients' homes and administered questionnaires, obtained resting arterial blood gas measurements, and conducted a standardized home exercise test while monitoring oxygen saturation using an oximeter. Measures of outcome: We evaluated the extent to which patients met HOP criteria that are based on the inclusion criteria of randomized trials showing the life-prolonging effects of domiciliary oxygen. We also assessed the extent to which the patients' oxygen prescription was consistent with the results of rest and exercise testing. 
T wo randomized trials have addressed the effect of domiciliary oxygen on the mortality of patients with COPD. 1,2 These trials provided convincing evidence that long-term oxygen therapy (LTOT) can extend life in some patients with COPD. In response, third-party health-care funders, including government agencies in many countries, provide coverage for domiciliary oxygen in eligible patients. The two randomized trials enrolled COPD patients with a resting Pao 2 of Ͻ 60 mm Hg. While such patients benefit from LTOT, generalization to other groups is less secure. Nevertheless, many would accept that patients with comparable levels of hypoxemia as a result of nonobstructive lung disease or chronic heart failure are also likely to live longer if they receive continuous oxygen therapy. Evidence is limited for other patient groups who may benefit, including those with transient nighttime desaturation and those with transient desaturation during exercise. In the former group, randomized trial evidence suggests a reduction in pulmonary artery pressures with oxygen, 3 but the effect on morbidity and mortality remains uncertain. Similarly, the effect of oxygen on symptoms, or morbidity and mortality, in patients who are normoxic at rest but desaturate on exercise has not been established.
Different jurisdictions show a varying willingness to generalize beyond COPD patients with rest hypoxemia. Whatever their eligibility criteria, thirdparty payers rely on physicians to make appropriate referrals for domiciliary oxygen. Appropriate referral requires an understanding of the criteria for LTOT, an awareness of the necessity for optimal treatment, and a period of stability before referral.
In our jurisdiction (Ontario, Canada; population, 11 million), physicians referring patients for government-reimbursed LTOT must provide evidence that patients meet criteria, including providing the results of a resting arterial blood gas measurement. Documentation of the persisting necessity for home oxygen relies on the documentation of oxygen saturation. This assessment is not standardized either in terms of the exercise employed or the target level of saturation.
In Ontario, Ͼ 15,000 patients receive LTOT under the Home Oxygen Program (HOP) of the Ministry of Health. Costs for this program rose from $18 million (Canadian) in 1985 to $55 million in 1995. We undertook this study to establish the proportion of patients currently receiving oxygen in whom its administration is warranted, and to evaluate the appropriateness of the oxygen dose they receive. This study is of importance to any health-delivery system that includes the provision of domiciliary oxygen.
Materials and Methods

Recruiting Patients
We identified all patients living in central Toronto, a city of 2.5 million people, or in the vicinity of Ottawa (metropolitan population, 1 million) receiving home oxygen funded by the HOP, who had a first-time oxygen application signed by a physician between July 1, 1995, and January 31, 1997. We excluded patients Ͻ 18 years old and those receiving oxygen for palliative care. We contacted the physicians of eligible patients; if the physicians approved of their patients' participation, we contacted the patients directly.
Patient Assessment
A respiratory therapist (RT) visited consenting patients in their homes, measured simple spirometry, and obtained information regarding medical history, use of oxygen, degree of activity, and extent to which the patients experienced dyspnea during daily living. Our criteria for adequate management of COPD patients included their receiving an inhaled ␤-agonist, an inhaled anticholinergic agent, and, if they experienced important nocturnal dyspnea, a trial of an oral theophylline. We stipulated that patients with heart failure should be receiving an angiotensinconverting enzyme inhibitor.
We considered patients to be unstable if they had been discharged from an acute-care hospital, or had had an exacerbation (defined as an increase in their breathing medication or the administration of antibiotics due to their breathing being worse) within 2 months, or if they said they were feeling much worse than usual. If patients were unstable, we delayed our assessment until they were stable.
Resting oximetry was measured after the patient had been seated for 20 min while breathing room air. If an Allen's test demonstrated adequate collateral flow and if the patient was not receiving an anticoagulant, the RT obtained an arterial blood gas sample. For patients whose Pao 2 was 56 to 59 mm Hg and who did not have ankle edema, the RT obtained from the physician's office the hematocrit prior to the administration of home oxygen.
If the saturation by pulse oximeter (Spo 2 ) was Յ 90% on room air, patients received supplemental oxygen in increments of 1 L/min at 20-min intervals until the lowest oxygen flow rate to keep the Spo 2 Ͼ 90% was established.
The patients then underwent a standardized exertional oximetry test in which they walked on the spot for 15 s alternating with 15 s of walking at their usual pace for a total of 5 min during which Spo 2 was monitored. The 5-min exercise period was repeated while patients received increments of 1 L/min in 20-min intervals until the lowest oxygen flow rate such that the Spo 2 Ն 90% for Ͼ 80% of the duration of the test was established. During each repetition of the test, we measured the mean Spo 2 during each of the 5 min of the test, and we also documented whether criteria (saturation Յ 88% for 2 continuous min) for exercise hypoxemia were met.
Patient Categorization
With respect to the indications for receiving oxygen, we classified patients in the following categories:
1. Pao 2 Յ 55 mm Hg breathing room air at rest. 2. Pao 2 of 56 to 59 mm Hg, with either edema or increased hematocrit (Ն 55).
3. Positive result on Allen's test (thus not possible to do arterial blood gas measurements) and a resting arterial saturation of oxygen of Յ 88%.
4. Pao 2 of 56 to 60 mm Hg and cor pulmonale or pulmonary hypertension as specified by physician.
5. Pao 2 of 56 to 60 mm Hg and saturation Յ 88% for 2 min on exercise, correctable with oxygen.
6. Oxygen prescribed for sleep hypoxemia. 7. No indication for oxygen. The first three categories represent the strongest indication for domiciliary oxygen: the Nocturnal Oxygen Therapy Trial and Medical Research Council criteria for life-prolonging oxygen or the equivalent in patients for whom we could not obtain arterial blood gas measurements. In addition to patients meeting these strict trial criteria, the HOP accepts patients in categories 4, 5, and 6 for home oxygen.
We also made note of individuals who, although they did not meet criteria, were funded by the HOP on "compassionate grounds." The "compassionate use" criterion is a response to specific physician appeals for exceptions to the set standards. A consultant reviews these appeals and decides whether they should be accepted.
Two raters, the RT who had collected audit data and the research associate coordinating the study, classified patients on the basis of the record of data collected during the assessment. For patients for whom the raters disagreed, one of the investigators (GHG) made the final decision.
The same raters also judged the appropriateness of oxygen prescriptions at rest and during exercise. Prescriptions could range from 0 to 5 L/min. For patients in whom saturation fell to Ͻ 85% for Ͼ 1 min of the test period despite receiving 4 L/min of oxygen, the raters were instructed to recommend further assessment. Again, a third reviewer (GHG) adjudicated any disagreements.
Statistical Methods
For each variable, we used standard methods to calculate proportions, means, and SDs. We calculated chance-corrected agreement () 4 between our two raters regarding whether there was any indication for oxygen (categories 1 to 6 vs category 7). We also calculated between the raters concerning rest and exercise prescription using a weighted with quadratic weights. 5 We also used weighted with quadratic weights to assess agreement between the patient's report of rest and exercise oxygen prescription and the record of rest and exercise prescription in the files of the HOP, as well as between both of these reports and the independently measured rest and exercise oxygen prescription. To explore a number of possible predictors of the appropriateness of oxygen use, we used logistic regression for independent variables (patient age, gender, city, urban or suburban, diagnosis, and whether the prescribing physician was a specialist or primary-care physician) and dependent variable (whether the prescription of oxygen was appropriate [categories 1 to 6]).
Results
Recruitment and Patient Characteristics
From a list of 557 potential participants, we found that 42 had died, 87 were no longer receiving oxygen, and 10 had moved out of the area. Of the remaining 418 patients, another 181 did not participate. The reasons included patients being too ill (n ϭ 86), language or social barriers (n ϭ 34), physician or patient refusal (n ϭ 51), and our inability to contact the patient (n ϭ 2). Another eight patients were consistently unstable throughout the study. Table 1 presents a comparison of the 237 patients who participated and the 181 eligible patients who did not participate for variables for which we have data from both groups. In both populations, most patients had COPD. Of the variables in which we had data for both groups, none showed a statistically significant difference between participants and nonparticipants.
Of the study participants, 70.1% were ex-smokers (mean, 50.2 pack-years) and another 10.3% continued to smoke. The mean FEV 1 of the COPD patients was 35.7% (21.5 Ϯ 41.0) of predicted, with a vital capacity of 53.4% (39.0 Ϯ 63.0). The pattern of medication use is what one would expect for appropriate prescribing in a population largely made up of those with severe chronic airflow limitation who suffer the typical complications (89.9% received inhaled ␤-agonists, 65.8% received inhaled ipratropium, 71.8% received inhaled or oral steroids, and 57.4% received a diuretic). Approximately one third of the patients were largely restricted to their homes, one third were relatively mobile, and one third spent a large amount of time outside the home.
We did not find any patients who were receiving suboptimal medications. In addition to the eight patients who remained unstable throughout the study, two patients who were initially unstable were reassessed after they had become stable. Of the 237 patients, 69 patients (29.1%) had been receiving home oxygen for Ͻ 18 months, 89 patients (37.6%) for 19 to 24 months, and 79 patients (33.3%) for Ͼ 2 years. We found only one significant predictor of an Among the 141 patients (59.5%) who met at least one criterion for appropriateness of home oxygen, 140 responded to a question concerning the degree of benefit. The distribution of responses for these patients was as follows: very beneficial, 82.1%; moderately beneficial, 15.7%; slightly beneficial, 2.1%; no benefit, 0%; and made condition worse, 0%. The distribution of responses to the same question among the 96 patients (40.5%) who did not meet any of the criteria for appropriateness for home oxygen was as follows: very beneficial, 87.5%; moderately beneficial, 8.3%; slightly beneficial, 3.1%; no benefit, 1.0%; and made condition worse, 0%.
Appropriateness of Oxygen Administration
Appropriateness of Oxygen Prescription
The weighted for our agreement on oxygen prescription at rest was 0.90 (95% CI, 0.84 to 0.95) and during exercise was 0.94 (95% CI, 0.91 to 0.97). Table 3 presents the proportion of patients receiving each oxygen prescription as defined by the three criteria: HOP documentation, patient report, and independent audit assessment. These would include those with no criteria for home oxygen, indications of oxygen only on exercise, and those with oxygen recommended for nocturnal hypoxemia. In general, our criteria would result in patients receiving less oxygen than they were using. We would recommend Ն 2 L/min of oxygen at rest for only 57 patients (24.1%) of the population. Results were very similar for exercise oxygen prescription: our recommended prescription was less than the patient was receiving, and less than that documented in the HOP application.
We found moderate agreement (, 0.52; 95% CI, 0.37 to 0.68) between the participant's report of how much oxygen they were receiving at rest and the HOP documentation of what they had been prescribed. The agreement between our recommended oxygen prescription at rest and either patients' report of oxygen use (, 0.17; 95% CI, 0.10 to 0.25) and the documentation provided to the HOP (, 0.08; 95% CI, 0.01 to 0.15) was extremely poor. Patient reports of oxygen prescription for exercise showed moderate agreement (, 0.63; 95% CI, 0.13 to 0.76) with the HOP; but again, agreement between our recommended oxygen prescription for exercise and either patients' report (, 0.26; 95% CI, 0.16 to 0.37) or the documentation provided to the HOP (, 0.15; 95% CI, 0.05 to 0.2.4) was very poor (Table 4) . †Includes two patients for whom prescription was reported as a fraction of inspired oxygen, rather than in liters per minute. ‡Includes one patient for whom prescription was reported as a fraction of inspired oxygen, rather than in liters per minute.
Discussion
The strengths of this study include the comprehensive survey of current oxygen recipients in a defined geographic area, the aggressive efforts to recruit all potentially eligible patients, and the rigorously standardized methodology of the measurement of resting and exercise oxygenation. A further strength was our ensuring that patients were receiving optimal medications and were clinically stable at the time of our assessment, as well as the attention to the reproducibility of our ratings. We have limited data describing the nonparticipants, but what we do have (age, sex, diagnosis, and reasons for oxygen prescription) suggests they were very similar to the participants. However, the small number of patients who did not participate because they were too ill may have been more likely to meet criteria than were the participants.
Our major finding is that 40.5% (95% CI, 34.3 to 46.8) of patients receiving home oxygen met neither the criteria of the third-party funder for home oxygen nor any criteria that strongly mandate domiciliary oxygen use. Subtracting those funded by the third party on compassionate grounds, there remained 32.1% (95% CI, 26.1 to 38.0) who did not meet known criteria. Despite this, each patient had been accepted by the HOP based on information at the time of their application. What are the possible reasons for this discrepancy?
One of the most plausible explanations for initial eligibility of those who proved to be ineligible during the audit is that patients were tested while still experiencing the adverse effects of an exacerbation. When the exacerbation was fully resolved, such patients may no longer have required oxygen. For example, Levi-Valensi and colleagues 6 found that 30% of patients meeting criteria for domiciliary oxygen after 1 month of apparent stability no longer met the same criteria after an additional 3 months of observation. Another possibility is that prolonged oxygen therapy may result in cardiopulmonary vascular changes that improve ventilation/perfusion matching and result in normoxia at rest. 7 Evidence for this phenomenon is weak, but we cannot exclude it as a possibility. Other possibilities include conscious or unconscious bias during testing for eligibility, given that testing protocols are not standardized. For instance, patients tested with overly vigorous exercise or without an adequate rest period prior to obtaining measurements may yield inappropriately reduced oxygen levels. Equipment calibration and reproducibility might be another source of error.
Almost all patients who did not meet criteria experienced at least moderate subjective benefit from home oxygen. Their experience represents either a placebo effect or an oxygen-related decrease in exertional dyspnea in daily activities. 8 Patients with COPD with a resting Pao 2 Ͼ 60 mm Hg and exercise hypoxemia show inconsistent improvement in laboratory exercise capacity with supplemental oxygen. 9 The only randomized trial addressing the effect of home oxygen on symptoms and healthrelated quality of life in patients with exercise hypoxemia who did not meet randomized trial inclusion criteria found no benefit. 10 These results suggest that placebo effects may play an important role in the subjective benefit of home oxygen.
We found not only a high rate of inappropriate oxygen use, but an unstandardized approach to determining oxygen flow rates. Flow rates tended to be higher than our criteria would dictate, and bore a very weak relationship with our suggested flow rates. Thus, it is likely that many patients were receiving greater flow rates than required, and some lower flow rates than would be optimal.
Smaller studies in other jurisdictions have also shown a high incidence of Pao 2 Ͼ 60 mm Hg in patients receiving domiciliary oxygen 11 and a ten- dency for patients to use more oxygen than necessary. 12 Ours is the first study to systematically examine the frequency of inappropriate oxygen use in a jurisdiction that had already implemented criteria based on the results of the British Medical Research Council trial and the Nocturnal Oxygen Therapy Trial.
Our results suggest that the HOP program could realize substantial savings (a 30% budget reduction would represent $16.5 million), by denying oxygen to those who are not eligible. A more appropriate choice of oxygen flow rates might achieve further cost reductions. On the one hand, we could view the reduction of "inappropriate oxygen" with satisfaction, noting not only cost savings but also an improved quality of life from the discontinuation of an unnecessary piece of equipment. On the other hand, we do not know whether denying patients home oxygen would result in a higher utilization of physician visits, emergency services, or hospital admissions. This important issue requires a trial of alternative organizational systems of oxygen delivery that would include health-services utilization as an outcome measure.
The Ontario criteria, and methods of establishing the need for oxygen therapy, resemble those of many other jurisdictions worldwide. The need for clinical stability is stated in almost all program criteria. Stipulation of an initial blood gas measurement is common, as are additional criteria to accommodate exercise and sleep hypoxemia. Rigorous follow-up as represented by this study is very uncommon. It is therefore likely that our findings are applicable to domiciliary oxygen programs in other countries. Our results highlight the considerable costs associated with LTOT, and the desirability of standardized methods for establishing oxygen prescriptions, particularly exercise prescriptions. Our findings suggest that objective evaluations of the necessity of oxygen administration some months after patients begin therapy are likely to identify a large proportion who do not meet current criteria. The cost of such additional visits must be included in the evaluation of this approach. We would estimate these costs to be below $75.00 per visit (United States) and therefore as being trivial relative to the potential benefits of appropriate selection. Education of referring physicians and patients as to the often-transient need for oxygen at home, particularly at a time of expedient discharge from hospital, would also be helpful. Specific criteria and standardized approaches to assess oxygen during exercise will also clarify the benefits of LTOT for individuals with respiratory conditions. However, changes in the organizational structure of assessment and delivery may well be necessary to achieve optimal health resource allocation in home oxygen programs throughout the world.
